# A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

> **NCT03594747** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 360 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03594747
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-30
- **Primary completion:** 2020-09-30
- **Final completion:** 2023-04-28
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594747, "A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03594747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*